Citigroup restated their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research note released on Wednesday morning. The firm currently has a GBX 1,400 ($18.84) price objective on the stock.

Several other equities research analysts have also recently commented on GSK. J P Morgan Chase & Co restated a neutral rating and set a GBX 1,330 ($17.90) price target on shares of GlaxoSmithKline in a research note on Wednesday. Investec cut GlaxoSmithKline to a hold rating and cut their price target for the stock from GBX 1,800 ($24.23) to GBX 1,390 ($18.71) in a research note on Monday, November 6th. Shore Capital restated a hold rating on shares of GlaxoSmithKline in a research note on Wednesday, September 20th. restated a buy rating and set a GBX 1,970 ($26.51) price target on shares of GlaxoSmithKline in a research note on Wednesday, September 13th. Finally, Bank of America set a GBX 1,450 ($19.52) price objective on GlaxoSmithKline and gave the stock a neutral rating in a research report on Wednesday, December 6th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. GlaxoSmithKline presently has an average rating of Hold and a consensus price target of GBX 1,562.86 ($21.03).

Shares of GlaxoSmithKline (LON:GSK) opened at GBX 1,295 ($17.43) on Wednesday. GlaxoSmithKline has a 52 week low of GBX 1,270 ($17.09) and a 52 week high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last released its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The business had revenue of GBX 784.30 billion during the quarter.

The firm also recently declared a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be paid a GBX 19 ($0.26) dividend. This represents a yield of 1.41%. The ex-dividend date is Thursday, November 9th.

In other news, insider Simon Dingemans acquired 1,076 shares of GlaxoSmithKline stock in a transaction dated Thursday, October 12th. The shares were acquired at an average cost of GBX 1,527 ($20.55) per share, with a total value of £16,430.52 ($22,113.76). Also, insider Urs Rohner acquired 473 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 25th. The stock was purchased at an average cost of GBX 1,518 ($20.43) per share, for a total transaction of £7,180.14 ($9,663.71). Over the last three months, insiders acquired 1,577 shares of company stock worth $2,400,086.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline (GSK) Given Neutral Rating at Citigroup” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/glaxosmithkline-gsk-given-neutral-rating-at-citigroup/1768894.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.